Kynam Capital Management Increases Stake in CytomX Therapeutics to 6.9%

Kynam Capital Management, LP, along with its general partner Kynam Capital Management GP, LLC and Yue Tang, has filed an amended Schedule 13G/A for CytomX Therapeutics, Inc. (CTMX). As of the event date on March 31, 2026, the filers reported a combined beneficial ownership of 15,013,093 shares of Common Stock, representing a 6.9% ownership stake in the company. This filing indicates an increase in holdings compared to previous reports where the ownership percentage was not specified or was effectively zero. The reporting persons share voting and dispositive power over the reported shares. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Kynam Capital Management is based in Princeton, New Jersey, and operates as an investment adviser. The shares represent a significant passive investment in the clinical-stage oncology-focused biopharmaceutical company.